Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 455-463

  Pazianas, Michael ^a   Clark, Emma M ^b   Eiken, Pia A ^c   Brixen, Kim ^d   Abrahamsen, Bo ^e,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HILLERØD HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

ADVERSE REACTIONS; BISPHOSPHONATES; OCULAR INFLAMMATION; OSTEOPOROSIS TREATMENT

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; STEROID; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; CONJUNCTIVITIS; DIABETES MELLITUS; EPISCLERITIS; EYE INFLAMMATION; FEMALE; HUMAN; IRIDOCYCLITIS; KERATITIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OSTEOPOROSIS; PRESCRIPTION; RHEUMATIC DISEASE; SARCOIDOSIS; SCLERITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; UVEITIS;

BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DIPHOSPHONATES; DRUG PRESCRIPTIONS; EYE DISEASES; FEMALE; HUMANS; MALE; OSTEOPOROSIS;

EID: 84873979722     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1783     Document Type: Article

References (38)

1. Siris ES., Bisphosphonates iritis. Lancet. 1993; 341: 436-7.
2. Ghose K, Waterworth R, Trolove P, Highton T., Uveitis associated with pamidronate. Aust NZ J Med. 1994; 24 (3): 320.
3. Macarol V, Fraunfelder FT., Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994; 118: 220-4.
4. Mbekeani JN, Slamovits TL, Schwartz BH, Sauder HL., Ocular inflammation associated with alendronate therapy. Arch Ophthalmol. 1999; 117: 837-8.
5. Ryan PJ, Sampath R., Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford). 2001; 40 (8): 956-7.
6. Malik AR, Campbell SH, Toma NM., Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol. 2002; 86: 1443.
7. Fraunfelder FW, Fraunfelder FT, Jensvold B., Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003; 135: 219-22.
8. Fietta P, Manganelli P, Lodigiani L., Clodronate induced uveitis. Ann Rheum Dis. 2003; 62: 378.
9. Subramanian PS, Kerrison JB, Calvert PC, Miller NR., Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol. 2003; 121 (9): 1335-6.
10. Adverse Drug Reactions Advisory Committee (ADRAC). Australian adverse drug reactions bulletin, vol. 23, no. 2 [Internet]. Woden, Australia: Therapeutic Goods Administration; 2004 April [cited. 2012 May 24]. Available from: http://www.tga.gov.au/hp/aadrb-0404.htm#a3.
11. Asensio Sánchez VM, Botella Oltra G, Carrasco E., Bisphosphonates and intraocular inflammation. Arch Soc Esp Oftalmol. 2004 Feb; 79 (2): 85-7.
12. Meaney TP, Musadiq M, Corridan PG., Diplopia following intravenous administration of pamidronate. Eye. 2004; 18: 103-14.
13. Durnian JM, Olujohungbe A, Kyle G., Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye. 2005; 19: 221-22.
14. El Saghir NS, Otrock ZK, Bleik JH., Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer. 2005; 5: 156.
15. Leung S, Ashar BH, Miller RG., Bisphosphonate-associated scleritis a case report review. South Med J. 2005; 98: 733-5.
16. Benderson D, Karakunnel J, Kathuria S, Badros A., Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma. 2006; 7: 145-7.
17. Richards JC, Wiffen SJ., Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea. 2006; 25: 1100-1.
18. Stack R, Tarr K., Drug-induced optic neuritis uveitis secondary to bisphosphonates. NZ Med J. 2006; 119: U1888.
19. Banal F, Briot K, Ayoub G, Dougados M, Roux C., Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol. 2008; 35 (12): 2458-59.
20. Kilickap S, Ozdamar Y, Altundag MK, Dizdar O., A case report: zoledronic acid-induced anterior uveitis. Med Oncol. 2008; 25 (2): 238-40.
21. Moore MM, Beith JM., Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust. 2008; 188: 370-1.
22. Phillips PM, Newman SA., Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol. 2008; 126 (1): 137-9.
23. Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC., Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med. 2008; 359 (13): 1410-1.
24. Colucci A, Modorati G, Miserocchi E, Di Matteo F, Rama P., Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm. 2009; 17: 267-8.
25. Tan YL, Sims J, Chee SP., Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica. 2009; 223 (3): 215-6.
26. McKague M, Jorgenson D, Buxton KA., Ocular side effects of bisphosphonates: a case report and literature review. Can Fam Physician. 2010 Oct; 56 (10): 1015-7.
27. Procianoy F, Procianoy E., Orbital inflammatory disease secondary to a single-dose administration of Zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int. 2010; 21: 1057-8.
28. Yang EB, Birkholz ES, Lee AG., Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol. 2010; 30: 94-5.
29. Fosamax® (alendronate sodium) prescribing information [Internet]. Whitehouse Station, NJ: Merck and Co., Inc; Mar [cited. 2012 May 24]. Available from. www.merck.com/product/usa/pi-circulars/f/fosamax/fosamax-pi.pdf.
30. Actonel® (risedronate sodium) prescribing information [Internet]. Cincinnati, OH: Procter and Gamble Pharmaceuticals, Inc; Dec [cited. 2012 May 24]. Available from. http://www.actonel.com/global/prescribing-information.pdf.
31. Boniva® (ibandronate sodium) prescribing information [Internet]. South San Francisco, CA: Genentech USA Inc; Jan [cited. 2012 May 24]. Available from. http://www.gene.com/gene/products/information/boniva/pdf/pi.pdf.
32. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
33. Lyles KW, Colõn-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357 (18): 1799-809.
34. French DD, Margo CE., Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008; 28 (6): 889-93.
35. Etminan M, Forooghian F, Maberley D., Inflammatory ocular adverse events with the use of oral bisphosphonates a retrospective cohort study. CMAJ. 2012 May 15; 184 (8): E431-4.
36. Mondelo N, Peluffo VA, Parma MD, Cointry GR, Capozza RF, Ferretti JL, Piccinni E, Montuori E., [Preclinical toxicology of bisphosphonates]. Medicina (B Aires). 1997; 57 (Suppl 1): 93-100.
37. Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Mönkkönen J., Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999 May; 8 (2): 109-18.
38. Afshari NA, Afshari MA, Foster CF., Inflammatory conditions of the eye associated with rheumatic diseases. Curr Rheumatol Rep. 2001; 3: 453-8.